DOI: 10.1055/s-00000069

Seminars in Liver Disease


A multicenter, randomized, double-blind, phase 3 study of ramucirumab (IMC-1121B) drug product and best supportive care (BSC) versus placebo and BSC as second-line treatment in patients with hepatocellular carcinoma following first-line therapy with sorafenib (REACH).
Available at: . Accessed January 11, 2012

Download Bibliographical Data

Search in: